QurAlis has filed a notice of an exempt offering of securities to raise $88,019,211.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, QurAlis is raising $88,019,211.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Kasper Roet played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About QurAlis
At QurAlis, we are pioneering the path to conquering ALS and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. Our proprietary platforms and unique biomarkers enable the design and development of precision medicines that act directly on disease-causing genetic alterations. We are advancing a deep pipeline of antisense oligonucleotides (ASOs) and small molecule programs addressing sub-forms of ALS that account for the majority of ALS patients. And, we are leveraging our insights, platforms, and successes in ALS to collaborate and expand our pipeline to other neurodegenerative diseases, such as frontotemporal-degeneration (FTD). Our goal is to halt disease progression and significantly improve outcomes. Our mission is to make a meaningful difference in patients lives.
To learn more about QurAlis, visit http://quralis.com/
Contact:
Kasper Roet, Chief Executive Officer
781-816-7031
https://www.linkedin.com/in/kasper-roet-9817395/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.